Dermatological toxicity of ixabepilone.
Ixabepilone is a new class of non-taxane microtubule-stabilizing agents. These agents bind tubulin, stabilize microtubules and, thus, block mitosis and result in cell death (1-8). In phase I studies, neutropenia was the only grade 4 toxicity while fatigue, anorexia and mucositis occurred as grade 3 toxicities. Neuropathy, myalgia, arthralgia, alopecia and gastro-intestginal toxicities also occurred at grades 1 and 2. No dermatological effects have been documented to date. Here, a case is reported of a 62-year-old woman with stage 4 breast cancer being treated with Ixabepilone (40 mg/m2) who developed a dermatological reaction not previously described as a toxicity from Ixabepilone therapy.
Conlin
Alison K
AK
Division of Oncology, Department of Internal Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA.
Vahdat
Linda
L
D001943:Breast Neoplasms / Q000188:drug therapy; D034261:Epothilones / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008875:Middle Aged; D050257:Tubulin Modulators / Q000009:adverse effects / Q000627:therapeutic use
D034261:Epothilones; D050257:Tubulin Modulators; C430592:ixabepilone